Jae Kim, MD
Gastroenterology · Mesa, AZNPI 1861578759
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.4%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 66.3% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $7,340 and has fallen 81.4% since, to $1,366 in 2025.
Across 288 payments — averaging $42.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Takeda Pharmaceuticals U.S.A., Inc.$552
- Johnson & Johnson$547
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$367
- Boston Scientific$317
- Daiichi Sankyo Inc.$286
- plus $2K from 29 others
Across 2 payments — averaging $14,700 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$16K
- Eli Lilly$13K
What the payments were for
- Speaking & faculty fees$6,70054%
- Food & beverage$5,56745%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $8,169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $552 |
| Johnson & Johnson | 32 | $547 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $367 |
| Boston Scientific | 4 | $317 |
| Daiichi Sankyo Inc. | 9 | $286 |
| Bristol Myers Squibb | 12 | $216 |
| Sanofi | 3 | $166 |
| Phathom Pharmaceuticals, Inc. | 7 | $151 |
| Pfizer | 9 | $149 |
| Intercept Pharmaceuticals, Inc. | 7 | $126 |
| Evoke Pharma, Inc. | 7 | $125 |
| Ardelyx, Inc. | 5 | $106 |
| Ironwood Pharmaceuticals, Inc | 6 | $104 |
| Gilead | 1 | $102 |
| Regeneron Healthcare Solutions, Inc. | 5 | $99 |
| Ipsen Biopharmaceuticals, Inc | 4 | $96 |
| Laborie Medical Technologies Corp. | 1 | $90 |
| Madrigal Pharmaceuticals | 3 | $76 |
| Nestle Healthcare Nutrition Inc. | 3 | $61 |
| QOL Medical, LLC | 2 | $53 |
| Merck | 2 | $41 |
| Boehringer Ingelheim | 3 | $39 |
| Averitas Pharma Inc. | 1 | $37 |
| Ferring Pharmaceuticals Inc. | 1 | $36 |
| Edwards Lifesciences | 1 | $28 |
| Lilly USA, LLC | 1 | $26 |
| UCB, Inc. | 2 | $25 |
| Biocon Biologics Inc | 1 | $24 |
| Mauna Kea Technologies, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Intra-sana Laboratories | 1 | $16 |
| Amgen | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Fresenius Kabi USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$5,300
- VIBERZI$2,800
- rezum Generator$138
- DUPIXENT$120
- INJECTAFER$120
- Epclusa$102
How this compares
$12,315 in reported general payments places this provider in the 80th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 15 | $47,388 |
| Pantoprazole Sodium | 153 | $1,859 |
| Omeprazole | 73 | $1,009 |
| Lactulose | 11 | $758 |
| Sucralfate | 18 | $356 |
| Famotidine | 48 | $322 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 18 | $278 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 12 | $150 |
| Amlodipine Besylate | 17 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $8,169 | $47,38815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 355 gastroenterology providers in Arizona.
Other gastroenterology in Mesa
- David LeffMesa$377K
- David TesslerMesa$191K
- Elisa FaybushMesa$30K
- Shahbaz QureshiMesa$25K
- Charles SapersteinMesa$25K
- Carlos Zapata AntigoniMesa$25K
- George WalkerMesa$15K
- Joel BrillParadise Valley$847K
- Daniel MelineScottsdale$795K
- David FleischerScottsdale$410K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.